L. A. Torre, F. Bray, R. L. Siegel, J. Ferlay, J. Lortet-tieulent et al., Global cancer statistics, CA Cancer J Clin, vol.65, pp.87-108, 2012.

J. M. Llovet, J. Zucman-rossi, E. Pikarsky, B. Sangro, M. Schwartz et al., Nat Rev Dis Primers, vol.2, p.16018, 2016.

J. C. Nault and A. Villanueva, Intratumor molecular and phenotypic diversity in hepatocellular carcinoma, Clin Cancer Res, vol.21, pp.1786-1788, 2015.

G. Sapisochin and J. Bruix, Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches, Nat Rev Gastroenterol Hepatol, vol.14, pp.203-217, 2017.

J. Bruix, M. Reig, and M. Sherman, Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma, Gastroenterology, vol.150, pp.835-853, 2016.

T. Yamashita, A. Kitao, O. Matsui, T. Hayashi, K. Nio et al., Gd-EOB-DTPAenhanced magnetic resonance imaging and alpha-fetoprotein predict prognosis of early-stage hepatocellular carcinoma, vol.60, pp.1674-1685, 2014.

S. J. Hectors, M. Wagner, O. Bane, C. Besa, S. Lewis et al., Quantification of hepatocellular carcinoma heterogeneity with multiparametric magnetic resonance imaging, Sci Rep, vol.7, p.2452, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01542017

A. Ueno, Y. Masugi, K. Yamazaki, M. Komuta, K. Effendi et al., OATP1B3 expression is strongly associated with Wnt/?-catenin signalling and represents the transporter of gadoxetic acid in hepatocellular carcinoma, J Hepatol, vol.61, pp.1080-1087, 2014.

J. Zucman-rossi, A. Villanueva, J. C. Nault, and J. M. Llovet, Genetic Landscape and Biomarkers of Hepatocellular Carcinoma, Gastroenterology, vol.149, pp.1226-1239, 2015.

J. M. Llovet, A. Villanueva, A. Lachenmayer, and R. S. Finn, Advances in targeted therapies for hepatocellular carcinoma in the genomic era, Nat Rev Clin Oncol, vol.12, pp.408-424, 2015.

J. M. Llovet, S. Ricci, V. Mazzaferro, P. Hilgard, E. Gane et al., SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma, N Engl J Med, vol.359, pp.378-390, 2008.

L. R. Roberts, Sorafenib in liver cancer--just the beginning, N Engl J Med, vol.359, pp.420-422, 2008.

J. L. Raoul, M. Kudo, R. S. Finn, E. J. Reig, M. Galle et al., Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond, Cancer Treat Rev, vol.68, pp.16-24, 2018.

, Electronic address: easloffice@easloffice.eu.; European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma, J Hepatol, vol.69, pp.182-236, 2018.

R. Salem, A. C. Gordon, S. Mouli, R. Hickey, J. Kallini et al., Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma, Gastroenterology, vol.151, pp.1155-1163, 2016.

E. Garin, X. Pallard, and E. J. , Does Y90 Radioembolization Prolong Overall Survival Compared With Chemoembolization in Patients With Hepatocellular Carcinoma?, Gastroenterology, vol.152, pp.1624-1625, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01520290

V. Vilgrain, H. Pereira, E. Assenat, B. Guiu, A. D. Ilonca et al., Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial, Lancet Oncol, vol.18, pp.1624-1636, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01727346

M. C. Wallace and S. L. Friedman, Hepatic fibrosis and the microenvironment: fertile soil for hepatocellular carcinoma development

, Gene Expr, vol.16, pp.77-84, 2014.

Y. Hoshida, A. Villanueva, M. Kobayashi, J. Peix, D. Y. Chiang et al., Gene expression in fixed tissues and outcome in hepatocellular carcinoma, N Engl J Med, vol.359, pp.1995-2004, 2008.

V. Hernandez-gea, S. Toffanin, S. L. Friedman, and J. M. Llovet, Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma, Gastroenterology, vol.144, pp.512-527, 2013.

B. Vogelstein, N. Papadopoulos, V. E. Velculescu, S. Zhou, L. A. Diaz et al., Cancer genome landscapes, Science, vol.339, pp.1546-1558, 2013.

K. Schulze, S. Imbeaud, E. Letouzé, L. B. Alexandrov, J. Calderaro et al., Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets, Nat Genet, vol.47, pp.505-511, 2015.
URL : https://hal.archives-ouvertes.fr/inserm-01159736

A. Fujimoto, M. Furuta, Y. Totoki, T. Tsunoda, M. Kato et al., Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer, Nat Genet, vol.48, pp.500-509, 2016.

J. Friemel, M. Rechsteiner, L. Frick, F. Böhm, K. Struckmann et al., Intratumor heterogeneity in hepatocellular carcinoma, Clin Cancer Res, vol.21, pp.1951-1961, 2015.

R. Xue, R. Li, H. Guo, L. Guo, Z. Su et al., Variable Intra-Tumor Genomic Heterogeneity of Multiple Lesions in Patients With Hepatocellular Carcinoma, Gastroenterology, vol.150, pp.998-1008, 2016.

J. C. Nault, M. Mallet, C. Pilati, J. Calderaro, P. Bioulac-sage et al., High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions, Nat Commun, vol.4, p.2218, 2013.

J. C. Nault, J. Calderaro, D. Tommaso, L. Balabaud, C. Zafrani et al., Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis, Hepatology, vol.60, pp.1983-1992, 2014.

H. Dubois-pot-schneider, K. Fekir, C. Coulouarn, D. Glaise, C. Aninat et al., Inflammatory cytokines promote the retrodifferentiation of tumorderived hepatocyte-like cells to progenitor cells, Hepatology, vol.60, pp.2077-2090, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01134747

F. Cabillic and A. Corlu, Regulation of Transdifferentiation and Retrodifferentiation by Inflammatory Cytokines in Hepatocellular Carcinoma, Gastroenterology, vol.151, pp.607-615, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01398435

G. He, D. Dhar, H. Nakagawa, J. Font-burgada, H. Ogata et al., Identification of liver cancer progenitors whose malignant progression depends on autocrine IL-6 signaling, Cell, vol.155, pp.384-396, 2013.

D. Sia, A. Villanueva, S. L. Friedman, and J. M. Llovet, Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis, Gastroenterology, vol.152, pp.745-761, 2017.

C. Pilati, E. Letouzé, J. C. Nault, S. Imbeaud, A. Boulai et al., Genomic profiling of hepatocellular adenomas reveals recurrent FRK-activating mutations and the mechanisms of malignant transformation, Cancer Cell, vol.25, pp.428-441, 2014.

M. Ziol, N. Poté, G. Amaddeo, A. Laurent, J. C. Nault et al., Macrotrabecular-massive hepatocellular carcinoma: A distinctive histological subtype with clinical relevance, Hepatology, vol.68, pp.103-112, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01744935

J. Calderaro, G. Couchy, S. Imbeaud, G. Amaddeo, E. Letouzé et al., Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification, J Hepatol, vol.67, pp.727-738, 2017.

R. Désert, S. Mebarki, M. Desille, M. Sicard, E. Lavergne et al., Fibrous nests" in human hepatocellular carcinoma express a Wntinduced gene signature associated with poor clinical outcome, Int J Biochem Cell Biol, vol.81, pp.195-207, 2016.

J. S. Lee, I. S. Chu, J. Heo, D. F. Calvisi, Z. Sun et al., Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling, Hepatology, vol.40, pp.667-676, 2004.

J. S. Lee, I. S. Chu, A. Mikaelyan, D. F. Calvisi, J. Heo et al., Application of comparative functional genomics to identify best-fit mouse models to study human cancer, Nat Genet, vol.36, pp.1306-1311, 2004.

L. M. Sargent, X. Zhou, C. L. Keck, N. D. Sanderson, D. B. Zimonjic et al., Nonrandom cytogenetic alterations in hepatocellular carcinoma from transgenic mice overexpressing c-Myc and transforming growth factor-alpha in the liver, Am J Pathol, vol.154, pp.1047-1055, 1999.

P. Kaposi-novak, J. S. Lee, L. Gòmez-quiroz, C. Coulouarn, V. M. Factor et al., Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype, J Clin Invest, vol.116, pp.1582-1595, 2006.

J. S. Lee, J. Heo, L. Libbrecht, I. S. Chu, P. Kaposi-novak et al., A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells, Nat Med, vol.12, pp.410-416, 2006.

H. Wold, Estimation of principal components and related models by iterative least squares, Krishnaiah PR. Multivariate analysis, pp.391-420, 1966.

S. Boyault, D. S. Rickman, A. De-reyniès, C. Balabaud, S. Rebouissou et al., Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets, Hepatology, vol.45, pp.42-52, 2007.
URL : https://hal.archives-ouvertes.fr/inserm-00130313

R. Désert, F. Rohart, F. Canal, M. Sicard, M. Desille et al., Human hepatocellular carcinomas with a periportal phenotype have the lowest potential for early recurrence after curative resection, Hepatology, vol.66, pp.1502-1518, 2017.

L. M. Mcshane, D. G. Altman, W. Sauerbrei, S. E. Taube, M. Gion et al., Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics. Reporting recommendations for tumor marker prognostic studies (REMARK), J Natl Cancer Inst, vol.97, pp.1180-1184, 2005.

D. G. Altman, L. M. Mcshane, W. Sauerbrei, and S. E. Taube, Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration, PLoS Med, vol.9, 2012.

S. Rebouissou, A. Franconi, J. Calderaro, E. Letouzé, S. Imbeaud et al., Genotype-phenotype correlation of CTNNB1 mutations reveals different ?-catenin activity associated with liver tumor progression, Hepatology, vol.64, pp.2047-2061, 2016.

C. Ng, S. Piscuoglio, and L. M. Terracciano, Molecular classification of hepatocellular carcinoma: The view from metabolic zonation, Hepatology, vol.66, 2017.

H. Clevers, Axin and hepatocellular carcinomas, Nat Genet, vol.24, pp.206-208, 2000.

S. Satoh, Y. Daigo, Y. Furukawa, T. Kato, N. Miwa et al., AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1, Nat Genet, vol.24, pp.245-250, 2000.

J. Zucman-rossi, S. Benhamouche, C. Godard, S. Boyault, G. Grimber et al., Differential effects of inactivated Axin1 and activated beta-catenin mutations in human hepatocellular carcinomas, Oncogene, vol.26, pp.774-780, 2007.

S. Abitbol, R. Dahmani, C. Coulouarn, B. Ragazzon, B. Mlecnik et al., deficiency in human and mouse hepatocytes induces hepatocellular carcinoma in the absence of ?-catenin activation, J Hepatol, vol.68, pp.1203-1213, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01807225

C. Guichard, G. Amaddeo, S. Imbeaud, Y. Ladeiro, L. Pelletier et al., Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma, Nat Genet, vol.44, pp.694-698, 2012.
URL : https://hal.archives-ouvertes.fr/inserm-00719917

S. Colnot, T. Decaens, M. Niwa-kawakita, C. Godard, G. Hamard et al., Liver-targeted disruption of Apc in mice activates beta-catenin signaling and leads to hepatocellular carcinomas, Proc Natl Acad Sci, vol.101, pp.17216-17221, 2004.

J. C. Allen, J. C. Nault, G. Zhu, A. Y. Khor, J. Liu et al., The transcriptomic G1-G6 signature of hepatocellular carcinoma in an Asian population: Association of G3 with microvascular invasion, Medicine (Baltimore), vol.95, 2016.

A. Villanueva, Y. Hoshida, C. Battiston, V. Tovar, D. Sia et al., Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma, Gastroenterology, vol.140, 2011.

S. Torrecilla, D. Sia, A. N. Harrington, Z. Zhang, L. Cabellos et al., Trunk mutational events present minimal intra-and inter-tumoral heterogeneity in hepatocellular carcinoma, J Hepatol, vol.67, pp.1222-1231, 2017.

D. Sia and J. M. Llovet, Liver cancer: Translating '-omics' results into precision medicine for hepatocellular carcinoma, Nat Rev Gastroenterol Hepatol, vol.14, pp.571-572, 2017.

D. Y. Chiang, A. Villanueva, Y. Hoshida, J. Peix, P. Newell et al., Focal gains of VEGFA and molecular classification of hepatocellular carcinoma, Cancer, vol.68, pp.6779-6788, 2008.

Y. Hoshida, S. M. Nijman, M. Kobayashi, J. A. Chan, J. P. Brunet et al., Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma, Cancer Res, vol.69, pp.7385-7392, 2009.

A. Lachenmayer, C. Alsinet, R. Savic, L. Cabellos, S. Toffanin et al., Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib, Clin Cancer Res, vol.18, pp.4997-5007, 2012.

R. H. Yuan, Y. M. Jeng, R. H. Hu, P. L. Lai, P. H. Lee et al., Role of p53 and ?-catenin mutations in conjunction with CK19 expression on early tumor recurrence and prognosis of hepatocellular carcinoma, J Gastrointest Surg, vol.15, pp.321-329, 2011.

K. Mise, S. Tashiro, S. Yogita, D. Wada, M. Harada et al., Assessment of the biological malignancy of hepatocellular carcinoma: relationship to clinicopathological factors and prognosis, Clin Cancer Res, vol.4, pp.1475-1482, 1998.

H. Hayashi, K. Sugio, T. Matsumata, E. Adachi, K. Takenaka et al., The clinical significance of p53 gene mutation in hepatocellular carcinomas from Japan, Hepatology, vol.22, pp.1702-1707, 1995.

O. Musso, M. Rehn, N. Théret, B. Turlin, P. Bioulac-sage et al., Tumor progression is associated with a significant decrease in the expression of the endostatin precursor collagen XVIII in human hepatocellular carcinomas, Cancer Res, vol.61, pp.45-49, 2001.

N. Théret, O. Musso, B. Turlin, D. Lotrian, P. Bioulac-sage et al., Increased extracellular matrix remodeling is associated with tumor progression in human hepatocellular carcinomas, Hepatology, vol.34, pp.82-88, 2001.

L. Pabic, H. Bonnier, D. Wewer, U. M. Coutand, A. Musso et al., ADAM12 in human liver cancers: TGFbeta-regulated expression in stellate cells is associated with matrix remodeling, Hepatology, vol.37, pp.1056-1066, 2003.

Z. Kan, H. Zheng, X. Liu, S. Li, T. D. Barber et al., Wholegenome sequencing identifies recurrent mutations in hepatocellular carcinoma, Genome Res, vol.23, pp.1422-1433, 2013.

V. Cerec, D. Glaise, D. Garnier, S. Morosan, B. Turlin et al., Transdifferentiation of hepatocyte-like cells from the human hepatoma HepaRG cell line through bipotent progenitor, Hepatology, vol.45, pp.957-967, 2007.
URL : https://hal.archives-ouvertes.fr/hal-00690471

S. Mebarki, R. Désert, L. Sulpice, M. Sicard, M. Desille et al., De novo HAPLN1 expression hallmarks Wnt-induced stem cell and fibrogenic networks leading to aggressive human hepatocellular carcinomas, Oncotarget, vol.7, pp.39026-39043, 2016.
URL : https://hal.archives-ouvertes.fr/inserm-01335675

A. Bengochea, M. M. De-souza, L. Lefrançois, L. Roux, E. Galy et al., Common dysregulation of Wnt/Frizzled receptor elements in human hepatocellular carcinoma, Br J Cancer, vol.99, pp.143-150, 2008.

B. Wang, L. Zhao, M. Fish, C. Y. Logan, and R. Nusse, Self-renewing diploid Axin2(+) cells fuel homeostatic renewal of the liver, Nature, vol.524, pp.180-185, 2015.

L. Fu, C. Zhang, L. Y. Zhang, S. S. Dong, L. H. Lu et al., Wnt2 secreted by tumour fibroblasts promotes tumour progression in oesophageal cancer by activation of the Wnt/?-catenin signalling pathway, Gut, vol.60, pp.1635-1643, 2011.

O. Miltiadous, D. Sia, Y. Hoshida, M. I. Fiel, A. N. Harrington et al., Progenitor cell markers predict outcome of patients with hepatocellular carcinoma beyond Milan criteria undergoing liver transplantation, J Hepatol, vol.63, pp.1368-1377, 2015.

D. Sia, Y. Jiao, I. Martinez-quetglas, O. Kuchuk, C. Villacorta-martin et al., Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features, Gastroenterology, vol.153, pp.812-826, 2017.

H. W. Sim and J. Knox, Hepatocellular carcinoma in the era of immunotherapy, Curr Probl Cancer, vol.42, pp.40-48, 2018.

M. Iñarrairaegui, I. Melero, and B. Sangro, Immunotherapy of Hepatocellular Carcinoma: Facts and Hopes, Clin Cancer Res, vol.24, pp.1518-1524, 2018.

M. Ringelhan, D. Pfister, T. O'connor, E. Pikarsky, and M. Heikenwalder, The immunology of hepatocellular carcinoma, Nat Immunol, vol.19, pp.222-232, 2018.

B. Mínguez, Y. Hoshida, A. Villanueva, S. Toffanin, L. Cabellos et al., Gene-expression signature of vascular invasion in hepatocellular carcinoma, J Hepatol, vol.55, pp.1325-1331, 2011.

S. Roessler, H. L. Jia, A. Budhu, M. Forgues, Q. H. Ye et al., A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients, Cancer Res, vol.70, pp.10202-10212, 2010.

E. Villa, R. Critelli, B. Lei, G. Marzocchi, C. Cammà et al., Neoangiogenesis-related genes are hallmarks of fast-growing hepatocellular carcinomas and worst survival. Results from a prospective study, Gut, vol.65, pp.861-869, 2016.

H. G. Woo, J. H. Lee, J. H. Yoon, C. Y. Kim, H. S. Lee et al., Identification of a cholangiocarcinoma-like gene expression trait in hepatocellular carcinoma, Cancer Res, vol.70, pp.3034-3041, 2010.

T. Yamashita, M. Forgues, W. Wang, J. W. Kim, Q. Ye et al., EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma, Cancer Res, vol.68, pp.1451-1461, 2008.

T. Yamashita, J. J. Budhu, A. Forgues, M. Yang, W. Wang et al., EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features, Gastroenterology, vol.136, pp.1012-1024, 2009.

C. Coulouarn, V. M. Factor, and S. S. Thorgeirsson, Transforming growth factor-beta gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer, Hepatology, vol.47, pp.2059-2067, 2008.

N. M. Anderson, P. Mucka, J. G. Kern, and H. Feng, The emerging role and targetability of the TCA cycle in cancer metabolism, Protein Cell, vol.9, pp.216-237, 2018.

R. Z. Shang, S. B. Qu, and D. S. Wang, Reprogramming of glucose metabolism in hepatocellular carcinoma: Progress and prospects, World J Gastroenterol, vol.22, pp.9933-9943, 2016.

Q. Huang, Y. Tan, P. Yin, G. Ye, P. Gao et al., Metabolic characterization of hepatocellular carcinoma using nontargeted tissue metabolomics, Cancer Res, vol.73, pp.4992-5002, 2013.

P. Luo, P. Yin, R. Hua, Y. Tan, Z. Li et al., A Large-scale, multicenter serum metabolite biomarker identification study for the early detection of hepatocellular carcinoma, Hepatology, 2017.

D. Beyo?lu, S. Imbeaud, O. Maurhofer, P. Bioulac-sage, J. Zucmanrossi et al., Tissue metabolomics of hepatocellular carcinoma: tumor energy metabolism and the role of transcriptomic classification, Hepatology, vol.58, pp.229-238, 2013.

Z. C. Nwosu, D. A. Megger, S. Hammad, B. Sitek, S. Roessler et al., Identification of the Consistently Altered Metabolic Targets in Human Hepatocellular Carcinoma, Cell Mol Gastroenterol Hepatol, vol.4, pp.303-323, 2017.

N. Senni, M. Savall, C. Granados, D. Alves-guerra, M. C. Sartor et al., ?-catenin-activated hepatocellular carcinomas are addicted to fatty acids, Gut, 2018.

, Cancer Genome Atlas Research Network. Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma, Cell, vol.169, pp.1327-1341, 2017.

S. K. Saha, C. A. Parachoniak, K. S. Ghanta, J. Fitamant, K. N. Ross et al., Mutant IDH inhibits HNF-4? to block hepatocyte differentiation and promote biliary cancer, Nature, vol.513, pp.110-114, 2014.

H. A. Edmondson and P. E. Steiner, Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies, Cancer, vol.7, pp.462-503, 1954.

F. T. Bosman and W. Health-organization, Who classification of tumours of the digestive system, 2010.

Z. D. Goodman, Neoplasms of the liver, Mod Pathol, vol.20, issue.1, 2007.

C. Berasain and M. A. Avila, Deciphering liver zonation: new insights into the ?-catenin, Tcf4, and HNF4? triad, Hepatology, vol.59, pp.2080-2082, 2014.

A. Braeuning, C. Ittrich, C. Köhle, S. Hailfinger, M. Bonin et al., Differential gene expression in periportal and perivenous mouse hepatocytes, FEBS J, vol.273, pp.5051-5061, 2006.

M. G. Holloway, G. D. Miles, A. A. Dombkowski, and D. J. Waxman, Liverspecific hepatocyte nuclear factor-4alpha deficiency: greater impact on gene expression in male than in female mouse liver, Mol Endocrinol, vol.22, pp.1274-1286, 2008.

A. Gougelet, C. Torre, P. Veber, C. Sartor, L. Bachelot et al., T-cell factor 4 and ?-catenin chromatin occupancies pattern zonal liver metabolism in mice, Hepatology, vol.59, pp.2344-2357, 2014.

J. D. De-certaines, T. Larcher, D. Duda, N. Azzabou, P. Eliat et al., Application of texture analysis to muscle mri: 1-what kind of information should be expected from texture analysis?, EPJ Nonlinear Biomed Phys, vol.3, p.3, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01140159

R. A. Lerski, J. D. De-certaines, D. Duda, W. Klonowski, G. Yang et al., Application of texture analysis to muscle mri: 2 -technical recommendations, EPJ Nonlinear Biomed Phys, vol.3, issue.2, 2015.

P. ,